Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or
reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by
federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price, corporate or other market conditions; fluctuations
in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
But if Congress increases
reimbursement rates without reforming the use of
federal funds
in school food budgets, the end result could be significant costs to taxpayers coupled with little improvement
in the quality of meals served.
If increases
in reimbursement rates prove desirable, the changes discussed here would help ensure that the added
federal funds are actually used to provide more nutritious school meals.
[34] This is comparable to the additional revenue that a 4.5 cent across - the - board increase
in the
federal reimbursement rate for all school lunches would generate.
For the first time
in over three decades it would increase the
federal reimbursement rate, by approximately six cents a meal.
Shows like Jamie Oliver's «Food Revolution,» and school districts like Chef Ann Cooper's former district
in Berkeley, CA and current district
in Boulder, CO, are often held up as examples of what's possible
in school food reform, yet it's seldom ever mentioned that
in each of these cases, far more money is being spent on those meals than the current
federal reimbursement rate — and far more than that
rate plus six cents.
In «severe need» schools, the
federal reimbursement rate is $ 1.76, compared to the usual $ 1.48.
Both candidates support an adjustment
in federal reimbursement rates to local hospitals, which currently favor Dutchess County at the expense of Ulster.
A section of President Obama's 2010 Affordable Care Act authorizes the
federal government to reduce Medicare
reimbursement rates by 1 % for hospitals that rank
in the top quartile for hospital - acquired conditions, or HACs.
Federal reimbursements are projected to increase from $ 194.7 million
in FY2013 to $ 201.1 million
in FY2014 with an increased
reimbursement rate, higher contribution of donated food, and increased participation
rate in the snacks and after - school program.